Drug Profile
Research programme: anti-cancer therapeutics - Ono Pharmaceutical/X-Chem
Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator X-Chem
- Developer Ono Pharmaceutical; X-Chem
- Class Antineoplastics; Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for research development in Cancer in USA
- 21 Mar 2017 Ono Pharmaceutical and X-Chem enter into a collaboration agreement for the development of small molecule anti-cancer therapeutics
- 21 Mar 2017 Early research in Cancer in USA (unspecified route)